Journal of Oncology Research and Treatment
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Case Report   
  • J Oncol Res Treat 2017. 2:1,

DCF (DOC+CDDP+5-FU) Therapy Led to Curative Resection in a Patient with Advanced Esophageal Carcinoma after the Failure of CF Therapy

Kazuma Kobayashi1*, Shun Yamaguchi1, Takuro Fujita1, Takahiro Ikeda1, Ayaka Ishii1, Shunsuke Murakami1, Kengo Kanetaka1, Fumihiko Fujita1, Kosho Yamanouchi1, Naomi Hayashida1, Chika Sakimura1, Sayaka Kuba1, Fusako Kawakami1, Taiiichiro Kosaka1, Amane Kitasato1, Masaaki Hidaka1, Akihiko Soyama1, Shinichiro Oono1, Yusuke Inoue1, Shinichiro Kobayashi1, Tamotsu Kuroki1, Susumu Eguchi1, Tomonori Tanaka2 and Naoe Kinoshita2
1Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
2Department of Pathology, Nagasaki University Hospital, , Nagasaki, Japan
*Corresponding Author : Kazuma Kobayashi M.D., Ph.D., Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1Sakamoto, Nagasaki City, Nagasaki 852-8501, Japan, Tel: 95-819-7316, Fax: 95-819-7319, Email: kazuma-k2013@nagasaki-u.ac.jp

Received Date: Dec 12, 2017 / Accepted Date: Dec 21, 2017 / Published Date: Dec 29, 2017

Abstract

In Japan, two courses of CF therapy followed by surgery are accepted as a standard treatment for stage II/III oesophageal cancer according to the result of the JCOG9907 trial. However, some cases experience insufficient anti-tumour effects with CF therapy. We experienced a case with oesophageal cancer that underwent curative resection and DCF therapy after the failure of CF therapy. The patient was a 51-year-old male who visited our department due to heart burn, back pain, and weight loss since July 2014. He was diagnosed with stage III (T3N2M0) oesophageal carcinoma and started neo adjuvant CF therapy on September 19, 2014. After the first course of CF, a CT scan showed enlarged lymph node swelling and swallowing disturbance was worsened. We attempted to start DCF therapy on October 29, 2014. The feasibility of this therapy was high, with manageable grade 2 diarrhoea and a transient high fever. Swallowing disturbance further subsided during the course of treatment. After DCF treatment, a CT scan showed shrinkage of LN swelling, as well as the primary lesion. We performed videoassisted thoracoscopic oesophagectomy and 3-field LN dissection. Pathological findings showed a grade 2 histological therapeutic effects by neoadjuvant chemotherapy and down staging of the tumour to stage II (T2N2M0) was attained, which indicated curative resection was achieved. If there is a discrepancy in the anti-tumour effect between the primary lesion and LNs by neoadjuvant CF therapy for stage II/III oesophageal cancer, then conversion to DCF therapy might be one of the treatment choices.

Keywords: DCF; Oesophageal cancer; Oncology

Citation: Kobayashi K, Yamaguchi S, Fujita T, Ikeda T, Ishii A, et al. (2017) DCF (DOC+CDDP+5-FU) Therapy Led to Curative Resection in a Patient with Advanced Esophageal Carcinoma after the Failure of CF Therapy. J Oncol Res Treat 2: 118.

Copyright: © 2017 Kobayashi K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top